Opinion: Generic ‘identity’ gets lost when companies juggle both generic and brand drugs
We think we know generic drug companies. They challenge patents held by brand firms. They litigate vigorously to overturn those patents. And they often win these challenges.
But what about “generic” companies that play both sides, earning revenue from generic and brand drugs? Do they have less incentive to do what generic firms should be doing?
